对抗nras突变黑色素瘤:从实验室到床边。

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2017-12-01 Epub Date: 2017-11-21 DOI:10.2217/mmt-2017-0023

Ileabett M Echevarría-Vargas, Jessie Villanueva

{"title":"对抗nras突变黑色素瘤:从实验室到床边。","authors":"Ileabett M Echevarría-Vargas, Jessie Villanueva","doi":"10.2217/mmt-2017-0023","DOIUrl":null,"url":null,"abstract":"“ Oncogenic NRAS plays a critical role in melanoma initiation and maintenance; however, to date there are no effective ways to directly block the activity of mutant NRAS. ” NRAS is the second most common oncogenic driver in melanoma, mutated predominantly at codon 61 in almost 30% of all melanomas [1] . Tumors bearing NRAS mutations are highly aggressive and are associated with shorter patient survival [2] . Despite the prevalence of NRAS mutations and the severity of the resulting disease, treatment for NRAS mutant melanoma has lagged far behind BRAF-mutant tumors. Here, we summarize the status of the most promising strategies, highlighting the successes and the gaps that remain to be ﬁlled. GTP guanine-nucleotide exchange mutant form of to GAPs, leading to NRAS activation and persistent signaling that triggers and","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2017-0023","citationCount":"7","resultStr":"{\"title\":\"COMBATING NRAS MUTANT MELANOMA: FROM BENCH TO BEDSIDE.\",\"authors\":\"Ileabett M Echevarría-Vargas, Jessie Villanueva\",\"doi\":\"10.2217/mmt-2017-0023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"“ Oncogenic NRAS plays a critical role in melanoma initiation and maintenance; however, to date there are no effective ways to directly block the activity of mutant NRAS. ” NRAS is the second most common oncogenic driver in melanoma, mutated predominantly at codon 61 in almost 30% of all melanomas [1] . Tumors bearing NRAS mutations are highly aggressive and are associated with shorter patient survival [2] . Despite the prevalence of NRAS mutations and the severity of the resulting disease, treatment for NRAS mutant melanoma has lagged far behind BRAF-mutant tumors. Here, we summarize the status of the most promising strategies, highlighting the successes and the gaps that remain to be ﬁlled. GTP guanine-nucleotide exchange mutant form of to GAPs, leading to NRAS activation and persistent signaling that triggers and\",\"PeriodicalId\":1,\"journal\":{\"name\":\"Accounts of Chemical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":16.4000,\"publicationDate\":\"2017-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/mmt-2017-0023\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Accounts of Chemical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/mmt-2017-0023\",\"RegionNum\":1,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2017/11/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/mmt-2017-0023","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/11/21 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 7

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

COMBATING NRAS MUTANT MELANOMA: FROM BENCH TO BEDSIDE.

“ Oncogenic NRAS plays a critical role in melanoma initiation and maintenance; however, to date there are no effective ways to directly block the activity of mutant NRAS. ” NRAS is the second most common oncogenic driver in melanoma, mutated predominantly at codon 61 in almost 30% of all melanomas [1] . Tumors bearing NRAS mutations are highly aggressive and are associated with shorter patient survival [2] . Despite the prevalence of NRAS mutations and the severity of the resulting disease, treatment for NRAS mutant melanoma has lagged far behind BRAF-mutant tumors. Here, we summarize the status of the most promising strategies, highlighting the successes and the gaps that remain to be ﬁlled. GTP guanine-nucleotide exchange mutant form of to GAPs, leading to NRAS activation and persistent signaling that triggers and

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.